Comparison of Rivaroxaban with low molecular weight heparin in the treatment of cancer associated venous thromboembolism (VTE) in a real world setting

Trial Profile

Comparison of Rivaroxaban with low molecular weight heparin in the treatment of cancer associated venous thromboembolism (VTE) in a real world setting

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Rivaroxaban (Primary) ; Low molecular weight heparin
  • Indications Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top